October 2026
Obesity affects more than 40% of U.S. adults, and for many people, losing weight can be difficult even with healthy eating habits and regular exercise. GLP-1 medications have become an important treatment option for obesity and weight management, but high prescription costs can prevent patients from accessing these therapies.
To help address affordability concerns, Medicare launched the Medicare GLP-1 Bridge Program, a temporary initiative that helps eligible Medicare Part D beneficiaries access certain GLP-1 weight loss medications at a reduced cost. This guide answers common questions about GLP-1 medications, Medicare coverage for weight loss drugs, eligibility requirements, covered medications, and program costs.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge Program is a temporary coverage program that helps eligible Medicare Part D beneficiaries access certain GLP-1 weight loss medications at a reduced cost. The program launched on July 1, 2026, and provides coverage for select GLP-1 drugs that are prescribed for weight management and obesity treatment.
What are GLP-1 medications?
GLP-1 medications are prescription drugs used to help manage blood sugar levels, reduce appetite, and support weight loss. These medications mimic a naturally occurring hormone called glucagon-like peptide-1 (GLP-1), which helps regulate hunger and digestion after eating. GLP-1 medications can:
- Slow stomach emptying
- Increase insulin production
- Reduce appetite
- Help patients feel fuller longer
- Provide cardiovascular protection, support liver health, and protect kidneys
Because of these effects, GLP-1 medications are commonly prescribed for type 2 diabetes, obesity, weight management, cardiovascular disease, and certain kidney-related conditions.
Does Medicare cover GLP-1 medications for weight loss?
In most cases, Medicare Part D does not cover GLP-1 medications when they are prescribed solely for weight loss. In most cases, Medicare Part D beneficiaries may be able to access GLP-1 medications for conditions such as diabetes, heart disease, and kidney disease.
The Medicare GLP-1 Bridge program was created to temporarily help qualifying Medicare Part D participants obtain coverage for select GLP-1 medications for weight loss while broader coverage policies continue to evolve.
Which GLP-1 medications are covered by the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge program currently covers several GLP-1 weight loss medications when prescribed for weight loss or weight management:
- Foundayo (orforglipron) is covered and is only available as an oral tablet.
- Wegovy (semaglutide) is covered as both an injection and a tablet.
- Zepbound (tirzepatide) is also covered, but only as a KwikPen.
Patients should confirm coverage and formulary requirements with their Medicare Part D plan or pharmacy before starting treatment.
Who qualifies for the Medicare GLP-1 Bridge program?
To qualify for the Medicare GLP-1 Bridge Program, beneficiaries must meet specific body mass index (BMI), health condition, and lifestyle modification counseling requirements. To be eligible, you must meet one of these three criteria:
- Your body mass index (BMI) is 35 or higher
- Your BMI is 30 or higher and you have at least one of these conditions:
- Diastolic heart failure
- Uncontrolled high blood pressure
- Chronic kidney disease at stage 3a or higher
- Your BMI is 27 or higher and you have at least one of these conditions:
- Prediabetes
- A previous heart attack or stroke
- Blocked arteries in your legs or arms (peripheral artery disease) with symptoms
Who is not eligible?
You may not qualify if:
- Your Medicare Part D plan already covers your GLP-1 medication
- You have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — these may already be covered through your regular Part D plan instead.
How much do GLP-1 medications cost under the Medicare GLP-1 Bridge program?
Eligible participants pay $50/month for their covered GLP-1 through the Medicare GLP-1 Bridge Program. This monthly cost does not apply toward a Medicare Part D deductible and remains the same whether or not a beneficiary has met their deductible or annual out-of-pocket maximum.
When does the Medicare GLP-1 Bridge program end?
As of September 2026, the Medicare GLP-1 Bridge program expires at the end of December 31, 2027. To learn more about the Medicare GLP-1 Bridge program, check out this Medicare fact sheet.
Because Medicare coverage policies can change, beneficiaries should regularly review Medicare announcements and speak with their pharmacist or healthcare provider to confirm current eligibility and coverage details.
This article is for informational purposes only, and does not constitute medical, legal, or other professional advice. Recipients should verify all details before acting and are solely responsible for ensuring that all provided services comply with applicable laws, regulations, rules, and requirements.
